

ACCESS CHINA
*Biotech Forum***Summer Showcase**
During Bio Convention Week

June 9 to 18th, 2021 (online event)

*The Largest Online Corporate Access Event Between China And Western Biopharma Industry***助力中国药企全球BD**

Invitation

The largest China oriented healthcare partnering event - We are honored to invite you to our “**ACCESS CHINA** Biotech Forum @ Bio Convention Week 2021”, which will take place between June 9th and 18th, 2021. The Summer event expects to host 100+ company presentations, 10 keynote speeches, and 1,000+ global participants during Bio Convention Week.

Effective partnering and China market assessment platform - **ACCESS CHINA** is the most effective deal-making platform for pharma and biotech leaders looking to enter in the Chinese market. We provide direct opportunities connecting the right partners for development, licensing, financing and commercial collaborations.

Company roadshows are divided into 4 sessions:

1. Global Out-Licensing Session Global pharmas looking for out-licensing opportunities in China	2. China Biotech Out-Licensing Session Chinese biotech looking for global out-licensing & partnering opportunities
3. China Asset M&A Session Chinese pharmas looking for domestic M&A and out-licensing opportunities	4. China Biotech Fundraising Session Chinese Biotech companies looking for fundraising

We look forward to welcoming you at our summer event in June!

Sincerely,

ACCESS CHINA Forum Organizing Committee



Summer Showcase Tentative Agenda



		9-Jun	10-Jun	11-Jun	15-Jun	16-Jun	17-Jun	18-Jun
China Time	Global Time	Wed	Thu	Fri	Tue	Wed	Thu	Fri
		Cross-border sessions			China Domestic sessions		Replay (VoD)	
9:30-11:30 am	ET (9:30-11:30 pm, Day-1)	Global Out-Licensing Session (US/Canada)			China Asset M&A & Licensing Session			
3:00-5:00 pm	CET (9:00-11:00am)	Global Out-Licensing Session (EU & APAC)			Biotech Fundraising Session			
9:00-11:00pm	ET (9:00-11:00 am) CET (3:00 -5:00pm)	China Biotech Out-Licensing Session						



Who should present ?

Global pharma/biotech companies:

- Looking for out-licensing opportunities in China
- With clinical stage pharmaceutical assets
- Focusing on Oncology, CNS, Cardiovascular, Ophthalmology, Orthopedics, Pediatrics, GI, and other therapeutic areas

Chinese pharma/biotech companies

- Looking for out-licensing opportunities in China or worldwide
- Looking for equity investment opportunities in China



Who are the attendees ?

- **BD and C-level executives from Chinese pharma/biotech companies** looking for in-licensing opportunities to enrich pipeline (Global Out-licensing session; China M&A & Licensing session)
- **BD and C-level executives from pharma/biotechs outside China** looking for in-licensing opportunities to enrich pipeline in China and other regions (Global Out-licensing session; China Biotech Innovation & Out-licensing session)
- **VCs and PEs** looking for pharma/biotech investment opportunities (Biotech Fundraising session)




Why CHINA ?



Licensing has become one of the fastest growing strategies by Chinese pharmas

China related licensing transactions significantly increased despite of COVID-19 in 2020. There were in **total 129 China related cross border licensing deals** including 36 out-licensing deals and 93 in-licensing deals, representing an increase of 59% YoY.



Why ACCESS CHINA Platform ?

1. Broader Chinese Strategic Company & Investor Coverage

Compared to other conferences such as Bio Convention or Bio Showcase, ACCESS CHINA has the broadest coverage of Chinese strategic companies and investors who are looking for in/out licensing opportunities.

2. Easier China Market Assessment

We gather interests for presenting companies within two weeks after the presentations, an easy and effective way to assess the level of interest in the Chinese market.

3. More Exposure via Different Channels

ACCESS CHINA promotes presenting companies through various channels including asset listing on platform, video roadshow on live day and on demand, asset report distribution to our members, and promoting to targeted investors through email and social media.



Apply to present @ ACCESS CHINA



To apply for a "Presenting Slot", you simply need to submit the **application form** accessible via the link below. Once approved by AC Forum Organizing Committee, you will be offered to present at ACCESS CHINA Forum. Presenting slots are based on a **first come, first serve basis**.

For Registration, please go to:

<https://biotechchina.org/register/>

ACCESS CHINA Online Partnering Day 3-Step Process



Step 1. Presentation Submission & Review Company submits application form with partnering objectives (licensing, capital raising, M&A, etc).

ACCESS CHINA Committee will review the opportunity in the related therapeutic areas and accept the application.

Step 2. Online Presentation YAFU Life Science banking team will help you to prepare and coordinate for the conference day.

Company will present either via recording presentation or live presentation (please let us know your preference in the application xls form). Presentation replay will be organized 7 days afterwards.

After the conference, YAFU will collect interests and feedbacks from Chinese investors and provide an "investor list name" the presenting company. *(free of charge)*

Step 3. Customized exposure & Deal Closing YAFU will expose Company to a larger and customized list based on our investor base in related therapeutic area (for engaged clients only).

Facilitate the signing of LOI/Term Sheet, Due Diligence, and closing of the transaction.

JOIN US WHEN YOU ARE READY

For Global Biopharma Companies

No need to wait for months to spend time and money for a physical event in China. As ACCESS CHINA has several Online Partnering Day events through the year, you are welcome to join us when you are ready.

For Chinese Biopharma Companies

ACCESS CHINA has strong coverage of pharmaceutical and biotech companies from North America, Europe, MENA and APAC regions. This offers you an ideal channel to meet with potential out-licensing or commercial partners in different regions.



Live

+

Replay

LIVE DAY

During the live showcase held at ACCESS CHINA Online Partnering Day, presenters can discuss their pipeline, R&D activities, fundraising goals, and expectations from China market. Event audiences will come from 2,000+ BD Directors & Executives from biopharma companies and PE/VCS.

REPLAY DAY

For investors missing the live presentations, a replay-day will be arranged one week later. This will give the presenters even broader exposure.

Contact us

For Registration, please go to:

<https://biotochina.org/register/>

To apply for roadshow slots, attendance, sponsoring, and media support.

Please contact:

- Wendi Xiang, Vice President : wxiang@yafocapital.com; +86 137 3368 5995
- Gian Dell Antonio, Vice President (EU) : gandrea@yafocapital.com; +44 7425 307 383

Organizers



Supporters



ACCESS CHINA Upcoming Events



YAFO Capital's ACCESS CHINA Quarterly Forum is a leading deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market, and for Chinese companies to enter the global markets.

雅法全球医疗
YAFO Life Science

SPRING
春
Mar. 18, 2021
Online

SUMMER
夏
June 2021
Online

AUTUMN
秋
September 2021
Online

WINTER
冬
January 2022
Online

ACCESS CHINA FORUM 2021

The Largest Corporate Access Event Between China And Western Biopharma Industry

America Asia Europe China

ACCESS CHINA Past Events

ACCESS CHINA is a series of events that YAFO organizes each year, including East Meets West Mixing Dinner @ JPM, ACCESS CHINA BD Forum @ BIO International Convention, CHINA BD Forum (September each year), and ACCESS CHINA Online Partnering. During 2020 we have helped 333 companies to present their products in front of global pharma and VC/PEs.

333

Companies

16500+

Views

2800+

Requests

600+

Assets





Previous Presenting Companies

American Companies



European Companies



Asian Companies



Greater China Companies





Previous attendees from China

 Servier 施维雅	 MSD 默沙东	 Bayer 拜耳	 BD	 Abbott 雅培
 Merck Serono 默克雪兰诺	 Fosun Pharma 复星医药	 Shanghai Pharma 上海医药	 Huadong Medicine 华东医药	 Yangtze River 扬子江药业
 Jemincare 济民可信	 Grand Pharma 远大医药	 Salubris 信立泰	 Tasly 天士力	 Cstone 基石药业
 Alphamab 康宁杰瑞	 CANbridge 北海康成	 GeneSci Pharma 金赛药业	 SciClone 赛生药业	 OnQuality Pharma 岸阁医药
 Sperogenix 曙方医药	 Reistone 瑞石生物	 Carephar 柯菲平	 Ark Biosciences 爱科百发	 AnHeart Therapeutics 葆元生物
 Triastek 三迭纪医药	 IASO 驯鹿医疗	 YZY Biopharma 友芝友生物	 Hinova 海创药业	 Epimab 岸迈生物
 Beijing Konruns 康辰药业	 HuiGene 辉大基因	 Neurofront 神领医药	 SinoTau 先通医药	 KONEE 康膝生物
 Livzon 丽珠医药	 CSPC 石药集团	 CR Pharma 华润医药	 Simcere Pharma 先声药业	 Luoxin Pharma 罗欣药业
 Sequoia Capital 红杉资本	 6 Dimensions Capital 通和毓承	 Cnorthern Light 北极光创投	 OrbiMed (China) 奥博资本	 Delos Capital
 IDG Capital IDG资本	 Kaitai Capital 凯泰资本	 Vivo Venture 维梧资本	 CBC Group	 Matrix Partners China 经纬中国
 VI Ventures 弘励创投	 YF Capital 云锋基金	 Morningside Ventures 晨兴创投	 Lyfe Capital 济峰资本	 Yonghua Capital 涌铎投资

Previous Keynote Speakers (Partial)



Opening Speech & China Biotech Innovation



Jeffrey Zhang
Summit Chair, CHBD

Founder of PROMED; Former Vice President of Wuxi AppTec; Successively served as the head of new business development of Pfizer China, director of Johnson & Johnson China's strategic market.

Cross-border Licensing Annual review



Sean Jiang CFA
CEO & Founder, YAFO Capital

20+ years Wall Street banking & investment experience with Roth Capital, Xiangcai Securities. Former China GM of ISI Group (Evercore).

Japan Market Opportunity for Chinese Pharmas



Steve Engen
Founder&President, Renexes LLC

20+ years of Japanese and American pharmaceutical industry experience, brought over dozen US pharmaceutical products to the Japanese market.

Bio-century Commercial section- the evolution of china pharma market



Tina Hou
Global Partner, Mckinsey

Tina leads the new-product-launch work at McKinsey's Pharmaceutical & Medical Products Practice in China and has extensive experience in product launch & commercialization.

Global Transaction Experience - MNC Perspective



Cynthia Wang
BD Head, Servier China

Cynthia has 19+ years of Healthcare/pharmaceutical industrial experience in China. She worked as Senior BD manager for Pfizer in Vaccine BD global M&A projects and managing full TAs of out-licensing BD activities.

Swiss Biotech Innovation



Michael Altorfer
CEO, Swiss Biotech Association

Dr. Michael Altorfer has more than 20 years of experience in the Swiss life science industry comprising both big pharma and smaller biotech organizations.

Booming biologics: business and investment impact on Med tech



Jimmy Jin
Senior BD Director
Becton Dickinson & Company China

Jimmy Jin is leading business development for BD China. Prior to joining BD, he has worked as director of business development at Thermo Fisher China and as senior consultant at Bain & Company. He and his team have completed 20+ investment and collaboration projects in the sector of medical device, IVD, bio-tech, and analytical instruments.

From pipeline to topline, from China to the world.



Jiaxi Xu
Chief Analyst, Industrial Securities

Dr. Xu was graduated from School of Life Sciences of Fudan University. He has rich research experience in pharma and insurance institutions. He led the team to win the No. 1 Best Analyst of New Wealth.